Compare, Analyse SUVEN LIFE with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUVEN LIFESCIENCES   TEVA PHARMA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
TEVA PHARMA
Dec-13
SUVEN LIFESCIENCES/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs3383,185-   
Low Rs1692,767-   
Sales per share (Unadj.) Rs52.11,827.8-  
Earnings per share (Unadj.) Rs6.8114.2-  
Cash flow per share (Unadj.) Rs8.6261.9-  
Dividends per share (Unadj.) Rs1.5099.95-  
Dividend yield (eoy) %0.63.4 17.6%  
Book value per share (Unadj.) Rs65.32,030.3-  
Shares outstanding (eoy) m127.28848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.91.6 298.8%   
Avg P/E ratio x37.126.1 142.4%  
P/CF ratio (eoy) x29.611.4 260.4%  
Price / Book Value ratio x3.91.5 265.0%  
Dividend payout %22.087.5 25.1%   
Avg Mkt Cap Rs m32,2722,523,394 1.3%   
No. of employees `0001.144.9 2.4%   
Total wages/salary Rs m6610-   
Avg. sales/employee Rs Th6,132.234,485.7 17.8%   
Avg. wages/employee Rs Th611.10-   
Avg. net profit/employee Rs Th803.52,154.3 37.3%   
INCOME DATA
Net Sales Rs m6,6351,549,958 0.4%  
Other income Rs m2420-   
Total revenues Rs m6,8771,549,958 0.4%   
Gross profit Rs m1,604424,457 0.4%  
Depreciation Rs m221125,285 0.2%   
Interest Rs m3830,444 0.1%   
Profit before tax Rs m1,587268,729 0.6%   
Minority Interest Rs m01,221 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-176,406 0.0%   
Tax Rs m718-3,281 -21.9%   
Profit after tax Rs m86996,825 0.9%  
Gross profit margin %24.227.4 88.3%  
Effective tax rate %45.2-1.2 -3,704.7%   
Net profit margin %13.16.2 209.8%  
BALANCE SHEET DATA
Current assets Rs m6,2321,046,836 0.6%   
Current liabilities Rs m1,490912,930 0.2%   
Net working cap to sales %71.58.6 827.3%  
Current ratio x4.21.1 364.7%  
Inventory Days Days8691 95.2%  
Debtors Days Days8396 86.1%  
Net fixed assets Rs m4,043506,251 0.8%   
Share capital Rs m1273,815 3.3%   
"Free" reserves Rs m8,1830-   
Net worth Rs m8,3101,721,710 0.5%   
Long term debt Rs m18792,528 0.0%   
Total assets Rs m10,3893,542,151 0.3%  
Interest coverage x43.19.8 438.6%   
Debt to equity ratio x00.5 0.5%  
Sales to assets ratio x0.60.4 146.0%   
Return on assets %8.73.6 243.0%  
Return on equity %10.55.6 186.0%  
Return on capital %19.54.9 395.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m3,8220-   
CASH FLOW
From Operations Rs m356246,983 0.1%  
From Investments Rs m-279-87,516 0.3%  
From Financial Activity Rs m-225-296,273 0.1%  
Net Cashflow Rs m-148-136,806 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 76.3 Rs / USD

Compare SUVEN LIFESCIENCES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare SUVEN LIFESCIENCES With: WYETH LTD  SHASUN PHARMA  PIRAMAL ENTERPRISES  TTK HEALTHCARE  ALEMBIC LTD  



Today's Market

Sensex Crashes 1,203 Points; IT and Banking Stocks Witness Selling(Closing)

Indian share markets extended losses in the first trading session of FY21, as the number of coronavirus cases in the country continued to rise.

Related Views On News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020 (The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock (Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout... (The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

How to Trade the Coronavirus Crash - Download this FREE Report Now
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
Free Report: The Secret to Increasing Your Trading Profits Daily!
Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!

SUVEN LIFESCIENCES SHARE PRICE


Apr 1, 2020 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

OTHER USEFUL LINKS

MARKET STATS